Literature DB >> 7594346

Lansoprazole for maintenance therapy of peptic ulcer disease: weekend full-dose or everyday half-dose administration?

E Hoshino1, N Umeda, J Sano, K Miki, N Yahagi, M Oka, M Kimura, H Miyashita.   

Abstract

Seventy-one patients with peptic ulcer (44 gastric ulcer and 27 duodenal ulcer patients) were enrolled in this study. After the ulcers had healed with 2 months of treatment with lansoprazole (LPZ) 30 mg/day, patients were divided into two groups: 43 in the half-dose q.d. group and 28 in the weekend full-dose group. Fourteen (23%) of the 43 patients in the half-dose q.d. group and 14 of the 28 (50%) in the weekend full-dose group failed to continue taking the drug for 6 months owing to poor compliance (p < 0.05). None of the 30 patients who continued to take the maintenance dose of LPZ experienced ulcer recurrence during the 6-month follow-up period, whereas 71% of the patients who stopped taking LPZ experienced recurrence (p < 0.01). In conclusion, maintenance therapy using the half-dose q.d. administration schedule was superior to weekend full-dose administration because of the better patient compliance and a lower ulcer recurrence rate.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7594346     DOI: 10.1097/00004836-199506002-00019

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  3 in total

1.  Lansoprazole decreases peripheral blood monocytes and intercellular adhesion molecule-1-positive mononuclear cells.

Authors:  T Ohara; T Arakawa
Journal:  Dig Dis Sci       Date:  1999-08       Impact factor: 3.199

Review 2.  Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders.

Authors:  P Richardson; C J Hawkey; W A Stack
Journal:  Drugs       Date:  1998-09       Impact factor: 9.546

Review 3.  Deprescribing versus continuation of chronic proton pump inhibitor use in adults.

Authors:  Taline A Boghossian; Farah Joy Rashid; Wade Thompson; Vivian Welch; Paul Moayyedi; Carlos Rojas-Fernandez; Kevin Pottie; Barbara Farrell
Journal:  Cochrane Database Syst Rev       Date:  2017-03-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.